Increasing clarithromycin resistance is dramatically reducing the efficacy of standard triple therapy for Helicobacter pylori eradication. Quadruple therapy is associated with high cure rates, yet its complex administration protocol hampers its acceptability for general use. A recent study has assessed the efficacy and safety of a novel, single-capsule bismuth-containing quadruple therapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Bismuth antimicrobial drugs serve as broad-spectrum metallo-β-lactamase inhibitors
Nature Communications Open Access 30 January 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Suerbaum, S. & Michetti, P. Helicobacter pylori infection. N. Engl. J Med. 347, 1175–1186 (2002).
O'Connor, A., Gisbert, J. P., McNamara, D. & O'Morain, C. Treatment of Helicobacter pylori infection 2010. Helicobacter 15 (Suppl. 1), 46–52 (2010).
Malfertheiner, P. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56, 772–781 (2007).
Megraud, F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53, 1374–1384 (2004).
Malfertheiner, P. et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 377, 905–913 (2011).
O'Morain, C. et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment. Pharmacol. Ther. 17, 415–420 (2003).
Laine, L. et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am. J. Gastroenterol. 98, 562–567 (2003).
Lee, B. H. & Kim, N. Quadruple or triple therapy to eradicate H. pylori. Lancet 377, 877–878 (2011).
Gene, E., Calvet, X., Azagra, R. & Gisbert, J. P. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment. Pharmacol. Ther. 17, 1137–1143 (2003).
Luther, J. et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am. J. Gastroenterol. 105, 65–73 (2010).
Gisbert, J. P. et al. Sequential therapy for Helicobacter pylori eradication: a critical review. J. Clin. Gastroenterol. 44, 313–325 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Gisbert, J. A new, single-capsule bismuth-containing quadruple therapy. Nat Rev Gastroenterol Hepatol 8, 307–309 (2011). https://doi.org/10.1038/nrgastro.2011.84
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2011.84
This article is cited by
-
Bismuth antimicrobial drugs serve as broad-spectrum metallo-β-lactamase inhibitors
Nature Communications (2018)
-
Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for H. pylori Infection
Digestive Diseases and Sciences (2014)
-
In vitro cytotoxicity of surface modified bismuth nanoparticles
Journal of Materials Science: Materials in Medicine (2012)
